aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis
November 15, 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis
aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update
November 07, 2024 16:01 ET
|
aTyr Pharma, Inc.
aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update
aTyr Pharma to Present at Upcoming Investor Conferences
October 31, 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma to present at upcoming investor conferences
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
October 08, 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal
October 02, 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal
aTyr Pharma to Participate in September Investor Conferences
August 21, 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma to Participate in September Investor Conferences
aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update
August 13, 2024 16:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update
aTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical Operations
August 06, 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical Operations
aTyr Pharma Announces Research Study with Stanford Medicine
July 30, 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma announces research study with Stanford Medicine to explore role of anti-NRP2 antibodies in glioblastoma multiforme (GBM), form of brain cancer.
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
June 03, 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”